MEI Pharma (MEIP) Climbs 35% Following Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib

November 30, 2021 7:18 AM

MEI Pharma (NASDAQ: MEIP) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found